AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1214706
Drug: Alice strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alice strain vaccine (AS) intranasally
Trial: 23660095
Drug: Anti-infection therapy
RxNorm normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-infection therapy within 1 hour after admission (Observation group)
Trial: 23660095
Drug: Anti-infection therapy
RxNorm normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-infection therapy 1-6 hours after admission (Control group)
Trial: 18674411
Drug: Rivastigmine capsules
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine capsules (3-12 mg/day)
Trial: 18200818
Drug: Angiotensin‐II receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin‐II receptor blockers (ARBs)
Trial: 18200818
Drug: Angiotensin‐converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin‐converting enzyme (ACE) inhibitors
Trial: 18200818
Drug: Calcium‐channel blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium‐channel blockers (CCBs)
Trial: 18595261
Drug: Beta‐blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta‐blockers
Trial: 15109470
Drug: Pretravel brochures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretravel brochures explaining the hazards of drug abuse
Trial: 15109470
Drug: Overall drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall drug use
Trial: 11687449
Drug: Full-dose (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose (10 microg of PRP antigen)
Trial: 11687449
Drug: One-half dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-half dose (5.0 microg of PRP antigen)
Trial: 11687449
Drug: One-third dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-third dose (3.3 microg of PRP antigen)
Trial: 9744695
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA)/non‐steroidal anti‐inflammatory drug (NSAID) intake before admission
Trial: 26386123
Drug: Axitinib/BSC (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib/BSC (5 mg twice-daily)
Trial: 23354535
Drug: B. monniera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B. monniera (Brahmi) extract 450 mg
Trial: 22214254
Drug: L-theanine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine (400 mg daily, 100 mg per tablet, two tablets twice daily)
Trial: 22214254
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical tasting chewable tablets)
Trial: 22214254
Drug: L-theanine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine (400 mg daily)
Trial: 19201576
Drug: Probiotic therapy
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic therapy (Bifidobacterium longum 2 x 10(9) CFU daily)
Trial: 19201576
Drug: Prebiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic therapy (8.0 g of psyllium daily)
Trial: 19201576
Drug: Synbiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic therapy (both probiotic and prebiotic treatments)
Trial: 15884251
Drug: 50 micrograms/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms/day of continuous transdermal estradiol with sequential transdermal norethisterone acetate (NETA) in daily doses of 170 micrograms in a single transdermal patch
Trial: 10659551
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation (Sara, Thai Nakorn Patana)
Trial: 1716790
Drug: Desmopressin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (0.3 micrograms/kg BW i.v.) + Dextran 70 (30 g i.v.)
Trial: 1716790
Drug: Dextran 70
RxNorm normalized name: Dextran 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 70 (30 g i.v.)
Trial: 6644348
Drug: 5 X
RxNorm normalized name: PAD,ABDOMINAL 5 X 9 STERILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 X 10(6) U/m2 weekly
Trial: 29490577
Drug: Medium-whey-protein (22 g·L‐1)
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-whey-protein (22 g·L‐1) CE drink (CW‐M)
Trial: 29490577
Drug: High-whey-protein (33 g·L‐1)
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-whey-protein (33 g·L‐1) CE drink (CW‐H)
Trial: 29490577
Drug: Low-carbohydrate CE
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate CE drink (CE‐L)
Trial: 27161620
Drug: Intensive antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive antihypertensive therapy (systolic BP <120 mm Hg)
Trial: 27161620
Drug: Standard antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antihypertensive therapy (systolic BP <140 mm Hg)
Trial: 22613901
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 or 10 mg/kg)
Trial: 22613901
Drug: Immunomodulator treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulator treatment (vs. treatment without immunomodulator) in UC patients
Trial: 22613901
Drug: Infliximab or
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab or immunomodulator treatment
Trial: 20146676
Drug: 3‐4 component
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐4 component therapy plus SCUF or CVVHF
Trial: 10582669
Drug: Permanent low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permanent low dose-rate I-125 seeds placement after resection
Trial: 8727171
Drug: Besipirdine 5
RxNorm normalized name: Nerispirdine
DrugBank: Nerispirdine (DB12714)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besipirdine 5 mg b.i.d.
Trial: 8727171
Drug: Besipirdine 20
RxNorm normalized name: Nerispirdine
DrugBank: Nerispirdine (DB12714)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besipirdine 20 mg b.i.d.
Trial: 8727171
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (combined besipirdine doses)
Trial: 8727171
Drug: Post-treatment assessment
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment assessment
Trial: 1744753
Drug: Educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program consisting of three sessions led by a specially trained RN, focusing on medication compliance, attack prevention, drug effects, relaxation exercises, and smoking cessation.
Trial: 7064898
Drug: 500 kcal
RxNorm normalized name: inf.formula,urea cycle disordr 6.5 gram-500 kcal/100 gram ORAL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 kcal 55 g protein natural food
Trial: 27649903
Drug: Mindfulness and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness and Acceptance-based Group Therapy (MAGT)
Trial: 27064996
Drug: Once-daily abacavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily abacavir + lamivudine
Trial: 27064996
Drug: Twice-daily abacavir
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily abacavir + lamivudine
Trial: 15330012
Drug: Chiropractic spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic spinal manipulative therapy (SMT)
Trial: 20061012
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Act d 1, Act d 2, Act d 4, and Act d 5
Trial: 3947525
Drug: Salbutamol nebulized
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol nebulized at 4 litres/min (1 mg)
Trial: 3947525
Drug: Salbutamol nebulized
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol nebulized at 8 litres/min (5 mg)
Trial: 25415250
Drug: Antibiotics (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (500 mg metronidazole plus 375 mg amoxicillin three times per day for 7 days) during the first, non‐surgical phase of periodontal therapy (T1)
Trial: 25415250
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during the first, non‐surgical phase of periodontal therapy (T1)
Trial: 25415250
Drug: Antibiotics during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics during the second, surgical phase of periodontal therapy (T2)
Trial: 25415250
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during the second, surgical phase of periodontal therapy (T2)
Trial: 23498850
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg tablet every 6 months)
Trial: 21255511
Drug: Manual titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual titration by respiratory therapist
Trial: 18245541
Drug: E75 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E75 vaccine (HER2/neu 369-377) + granulocyte macrophage colony-stimulating factor, given intradermally to previously treated, disease-free NP breast cancer patients.
Trial: 16476069
Drug: Mitogenic bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitogenic bovine whey extract (2.5 mg/mL)
Trial: 16476069
Drug: Mitogenic bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitogenic bovine whey extract (10.0 mg/mL)
Trial: 9792996
Drug: Gastrin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastrin infusion at 5 pmol kg‐1 h
Trial: 9792996
Drug: Gastrin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastrin infusion at 15 pmol kg‐1 h
Trial: 9792996
Drug: Low-dose gastrin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose gastrin stimulated acid output
Trial: 9792996
Drug: High-dose gastrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose gastrin stimulated acid output
Trial: 9792996
Drug: Plasma PP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma PP levels during gastrin‐17 infusion
Trial: 3144329
Drug: Metoprolol 50
RxNorm normalized name: metoprolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg or 100 mg twice daily
Trial: 3144329
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg or 240 mg twice daily
Trial: 30475967
Drug: Nut group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nut group (60 g of a mixture of nuts/d)
Trial: 28112077
Drug: Dietary cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary cholesterol (600 mg/d)
Trial: 28112077
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (2 g/d)
Trial: 16780670
Drug: Basic internal
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic internal medication (Control)
Trial: 10654017
Drug: Oral metronidazole;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metronidazole; 20 courses (18 empiric)
Trial: 10654017
Drug: Oral vancomycin;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vancomycin; 10 courses (8 empiric)
Trial: 1420042
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous propofol infusion
Trial: 1420042
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous midazolam infusion
Trial: 1420042
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous sedation
Trial: 2864258
Drug: Hydroxyzine 20
RxNorm normalized name: pentaerythritol/hydroxyzine 20 mg-10 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 20 mg
Trial: 32044
Drug: Clemastine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine 3 mg
Trial: 2864258
Drug: Azatadine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azatadine 3 mg
Trial: 2864258
Drug: Compound score
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound score (Hydroxyzine)
Trial: 30880909
Drug: Seawater spray
RxNorm normalized name: Sodium Chloride 2600 mg in 100 mL NASAL SPRAY [NasalAsalt All-Natural Seawater]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seawater spray (Quinton®) five times daily
Trial: 25268516
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg once daily for a maximum of 28 days
Trial: 22985805
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for a maximum of 28 days
Trial: 25424809
Drug: MenC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenC vaccine
Trial: 16298658
Drug: Daclizumab 1
RxNorm normalized name: daclizumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 1 mg/kg/dose every 14 days for 5 doses (Group I, n = 107)
Trial: 16298658
Drug: Daclizumab 2
RxNorm normalized name: daclizumab 25 MG per 5 ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 2 mg/kg/dose every 14 days for 2 doses (Group II, n = 113)
Trial: 16298658
Drug: No antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibody induction (Group III, n = 78)
Trial: 16298658
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups received tacrolimus (TAC), mycophenolate mofetil (MMF), and steroids
Trial: 7767531
Drug: 4% lidocaine
RxNorm normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% lidocaine (5 cc)
Trial: 7767531
Drug: Saline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (5 cc)
Trial: 2272043
Drug: 3.0 g/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g/m2 AraC
Trial: 2272043
Drug: 1.0 g/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/m2 AraC
Trial: 31400337
Drug: Vasopressin infusion
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin infusion for 24 hours after cardiopulmonary bypass
Trial: 19103732
Drug: High-dose epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose epirubicin with cyclophosphamide (HEC)
Trial: 19103732
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose of epirubicin, 60 mg/m(2) (EC)
Trial: 19103732
Drug: Classical oral
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical oral cyclophosphamide, methotrexate, and fluorouracil (CMF)
Trial: 12771114
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate, n = 8506)
Trial: 10720165
Drug: Walnut diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut diet (43-57 g/d, 12.5% of energy from walnuts)
Trial: 9352475
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g inositol
Trial: 24627301
Drug: Zolpidem 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 40 mg
Trial: 3985604
Drug: Tinidazole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (50 mg/kg of body weight to a maximum of 2 g)
Trial: 3985604
Drug: Metronidazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (60 mg/kg of body weight to a maximum of 2.4 g)
Trial: 3985604
Drug: Metronidazole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (50 mg/kg of body weight to a maximum of 2 g daily for 3 days)
Trial: 30907345
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment (psychological and behavioral intervention + biofeedback)
Trial: 30276476
Drug: Curcumin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500 mg/day for 3 days)
Trial: 21935584
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine (GlaxoSmithKline Biologicals), 2 doses 42-56 days apart, N=371
Trial: 21935584
Drug: MMR +
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR + V (Priorix™ and Varilrix™), 1 dose each administered simultaneously, followed by another MMR vaccination 42-56 days later, N=123
Trial: 17604960
Drug: Low-dose anthracycline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose anthracycline treatment
Trial: 16139696
Drug: Mandibular two‐implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular two‐implant overdentures (IOD; n=54)
Trial: 12474023
Drug: Atorvastatin Na+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin Na+
Trial: 30369433
Drug: 0.5-mg/kg ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-mg/kg ketamine
Trial: 30369433
Drug: 0.2-mg/kg ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2-mg/kg ketamine
Trial: 25451556
Drug: n‐3 PUFAs/LC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 PUFAs/LC n‐3 PUFAs intake (fish/shellfish, fish oil supplements, perilla oils) for 24 months
Trial: 21455075
Drug: i-gel device
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel device
Trial: 18704870
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy module (EG 2)
Trial: 12474114
Drug: Ayahuasca (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (0.6 mg and 0.85 mg DMT/kg body weight)
Trial: 10095919
Drug: Oral antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibacterial drugs for uncomplicated pneumonia
Trial: 8861134
Drug: High dietary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dietary magnesium (315 mg/d)
Trial: 8861134
Drug: Low dietary
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dietary magnesium (115 mg/d)
Trial: 8861134
Drug: High dietary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dietary boron (3.23 mg/d)
Trial: 8861134
Drug: Low dietary
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dietary boron (0.23 mg/d)
Trial: 2101950
Drug: Salbutamol via
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol via metered-dose inhaler (MDI)
Trial: 7380993
Drug: Oral Metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Metoclopramide (10 mg)
Trial: 7380993
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg) during dopamine infusion
Trial: 29807495
Drug: Latina Breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latina Breast Cancer Survivorship Intervention (telephone-based, 3 education sessions weekly, 6 support calls)
Trial: 23248895
Drug: Multi-directional power
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-directional power toothbrush (Oral-B Professional Deep Sweep TRICLEAN 1000)
Trial: 18543584
Drug: Dexibuprofen tablets
RxNorm normalized name: Ibuprofen
DrugBank: Dexibuprofen (DB09213)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexibuprofen tablets (400 mg)
Trial: 18543584
Drug: Racemic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Racemic ibuprofen tablets (400 mg)
Trial: 16633363
Drug: Immediate consolidation
RxNorm normalized name: BAG,LEG LARGE CONSOLIDATED #0932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate consolidation with high-dose chemotherapy and hematopoietic support
Trial: 12941199
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies (C225 and ABX‐EGF) and tyrosine kinase inhibitors (ZD1839 and OSI‐774)
Trial: 12941199
Drug: Inhibitors of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors of farnesyl transferase (R115777 and SCH66336)